Escalating immunomodulatory therapy of multiple sclerosis - 1. Supplement;Immunmodulatorische stufentherapie der multiplen sklerose. 1. Ergänzung: Dezember 2000

Nervenarzt

Volumn 72, Issue 2, 2001, Pages 150-157

  Buttner U ^a   Chofflon, M ^a   Hess, K ^a   Kappos, L ^a   Kesselring, J ^a   Ludin, H P ^a   Schluep, M ^a   Vaney, C ^a   Baumhackl, U ^a   Berger, T ^a   Deisenhammer, F ^a   Freimuller M ^a   Hartung, H P ^a   Kollegger, H ^a   Kristoferitsch, W ^a   Lassmann, H ^a   Markut, H ^a   Vass, K ^a   Altenkirch, H ^a   Boese, J ^a   Gass, A ^a   Gehlen, W ^a   Goebels, N ^a   Haas, J ^a   Haferkamp, G ^a   Heidenreich, F ^a   Heitmann, R ^a   Hemmer, B ^a   Hohlfeld, R ^a   Janzen, R W C ^a   Jugelt E ^a   Kolmel W ^a   Konig N ^a   Lowitzsch, K ^a   Manegold, U ^a   Melms, A ^a   Mertin, J ^a   Petereit, H F ^a   Pette, M ^a   Pohlau D ^a   Poser, S ^a   Sailer, M ^a   Schmidt, S ^a   Schock, G ^a   Schulz, M ^a   Seidel, D ^a   Sommer, N ^a   Stangel, M ^a   Stark, E ^a   Stoll, G ^a   Weinrich, W ^a   Wietholter H ^a   Zettl, U K ^a   Zipp, F ^a   Zschenderlein, R ^a   Bayas, A ^a   Chan, A ^a   Flachenecker, P ^a   Gold, R ^a   Grauer, O ^a   Jung, S ^a   Kallmann, B ^a   Leussink, V ^a   Maurer M ^a   Rieckmann, P ^a   Toyka, K V ^a   Weilbach, F X ^a   more..

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Consensus; Immunomodulation; Multiple sclerosis; Therapy

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MITOXANTRONE;

ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; RELAPSE; TREATMENT FAILURE;

ACUTE DISEASE; ADJUVANTS, IMMUNOLOGIC; AUSTRIA; AZATHIOPRINE; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0035116740     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050729     Document Type: Article

References (53)

1. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
2. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis
3. Detection of ventricular enlargement in patients at the earliest clinical stage of MS
4. Development of new lesions on serial T2-weighted MRI increases the risk of the early development of MS following a clinically isolated syndrome
5. Combination therapy with glatiramer acetate (Copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis
6. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
7. Interferon beta la (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study
8. The effect of glatiramer acetate (Copax-one®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): A multi-center, randomized, double-blind, placebo-controlled study extended by open label treatment
9. A comparative study of the relative bioavailability of different nterferon beta preparations
10. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
11. Long-term efficacy of interferon-beta 1a (Rebif) in relapsing-remitting MS: 4-Years results of the PRISMS study
12. The 5-year risk of MS after optic neuritis
13. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
14. Interferon beta-1 b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
15. TNF neutralization in M5 - Results of a randomized, placebo-controlled multicenter study
16. Mitoxantrone in progressive multiple sclerosis (MS): A placebo-controlled, randomized, observer-blind European phase III multicenter study - Clinical results
17. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
18. Sustained clinical benefitsof glatiramer acetate in relapsing remitting multiple sclerosis patients observed for 6 years
19. Summary measure statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis
20. Understanding multiple sclerosis: Lessons from pathology
21. Relapsing-remitting multiple sclerosis: What is the potential for combination therapy?
22. Behandlung der schubförmigen Multiplen Sklerose (MS) mit rekombinanten interferon-beta präpraten: Aspekte zur pharmakologie und dosierung
23. Subcutaneous IFN beta-1b in secondary progressive multiple sclerosis
24. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis
25. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
26. Immunmodulatorische stufentherapie der multiplen sklerose
27. Quality of life in multiple sclerosis
28. Multiple Sclerosis disease activity may determine whether immunoglobulin (IVIg) administration enhances or worsens visual function in patients with severe, stable optic neuritis (ON)
29. Treatment of multiple sclerosis: Recent trials and future perspectives
30. Linomide in relapsing and secondary progressive MS
31. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
32. Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in mutiple sclerosis
33. Evidence of interferon beta-1a dose response in relapsing-remitting multiple sclerosis
34. Results of the 3-year, double-blind, placebo-controlled study of interferon beta-la (Rebif) in secondary progressive MS
35. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
36. Serial monthly MRI in early onset multiple sclerosis
37. Injecting rationale into interferon-beta therapy
38. Cladribine and progressive MS
39. Escalating immunotherapy of multiple sclerosis
40. Doctors and patients don't agree: Cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis
41. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
42. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
43. Quantitative MRI in patients with clinically isolated syndromes of demyelination
44. Targeting immunotherapy in multiple sclerosis
45. A Wallerian degenration pattern in patients at risk for MS
46. Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF, and HLA findings
47. Placebo controlled pilot trial to study the remyelinating potential of intravenous imunoglobulins in multiple sclerosis
48. Multiple approaches to multiple sclerosis
49. Exploratory treatment trials in multiple sclerosis using MRI: Sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled paralel groups
50. Disease modifying treatments for multiple sclerosis
51. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
52. Multiple Sklerose ñ Aktuelle Übersicht zu fehlgeschlagenen und abgebrochenen Therapiestudien